GSK and iTeos will share in the work and the expenses for global development of EOS-448, according to the agreement. They’ll also share in commercializing the drug—if it’s approved.

--iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its ...

GlaxoSmithKline GSK announced an agreement to acquire joint development and commercialization rights to iTeos Therapeutics’ ITOS early-stage cancer candidate, EOS-448, an anti-TIGIT monoclonal ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Britain's GlaxoSmithKline Plc (GSK.L) has agreed to pay up to $2 billion to iTeos Therapeutics Inc (ITOS.O) to develop and sell a potential cancer treatment together, the companies said on Monday.

GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments.

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of ...

Today's biotech news roundup includes thoughts on hopes for TIGIT and questions about Summit Therapeutics' ivonescimab data in lung cancer.

Shares of iTeos Therapeutics Inc. soared 58.5% in premarket trading on Monday after the company announced a deal with GlaxoSmithKline to develop and commercialize an experimental cancer therapy ...

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell ...